The Carlat Psychiatry Podcast Hidden Gems: Pramipexole Part I
13 snips
Feb 23, 2026 A lively discussion of pramipexole’s D3 selectivity and why that matters for motivation and anhedonia. They explore brain circuits tied to reward, causes of dopamine decline, and when pramipexole might help tough-to-treat depression. Clinical trial evidence, long‑term durability, and safety considerations get spotlighted. Closing teases dosing details to come.
AI Snips
Chapters
Books
Transcript
Episode notes
A Clinician's Doubt Then Change Of Mind
- Chris Aiken hesitated to endorse pramipexole because his bipolar specialty and regional inflammation rates might bias his experience.
- A new English trial nevertheless convinced him to move pramipexole up to second-line for treatment-resistant depression.
Large Yearlong Trial Raised Pramipexole's Place In Algorithm
- A recent large UK trial enrolled truly treatment-resistant patients (avg 3.5 antidepressant failures) and showed durable pramipexole benefit for a full year.
- The trial's size and one-year placebo control distinguish it, boosting pramipexole from third-line to second-line in Aiken's algorithm.
D3 Targeting Explains Pramipexole's Antidepressant Effect
- Pramipexole is a D3-selective dopamine agonist that targets motivation and reward circuits implicated in anhedonia.
- D3 is concentrated in the nucleus accumbens, explaining benefits for amotivation, psychomotor slowing, and anhedonia in depression.
